+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05369351

Evaluating Mirabegron Added to Standard Treatment for Intracerebral Hemorrhage Patients to Assess Safety and Brain Recovery

Led by Tianjin Medical University General Hospital · Updated on 2026-10-20

25

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Intracerebral hemorrhage ICH causes 10-15% of all strokes and currently lacks effective drug treatments. Inflammation after ICH worsens brain damage by disrupting barriers and causing swelling near the bleeding area, which harms neurological function. Research shows that certain bone marrow cells produce anti-inflammatory monocytes to protect the brain after ICH. Stimulating a specific receptor called 3 adrenergic receptor may increase these protective cells, reducing inflammation and brain swelling. This trial evaluates the safety and effects of the drug mirabegron, a 3 adrenergic receptor agonist, in people with ICH. Participants will be randomly assigned to one of two groups one group will receive standard treatment plus mirabegron at a dose of 50 mg per day, started within 72 hours of symptom onset and continued for 7 days the other group will receive standard treatment alone. The study uses a single-blind design and compares the outcomes between these groups to assess the potential benefits and safety of adding mirabegron to usual care. During the study, participants will undergo computed tomography CT scans to measure brain swelling and hematoma size at 7 and 14 days. Neurological functioning will be evaluated using NIHSS scores at the same time points, and functional independence will be assessed at 90 days. Researchers will also monitor immune cells in blood, adverse reactions to the drug, and mortality rates up to 90 days. The study aims to follow participants until November 2027, with primary outcome data collected by August 2027.

CONDITIONS

Brief Title

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Research Team

H

Handong Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here